178 results about "Human platelet" patented technology

The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof:

• a) It specifically binds to human platelet membrane glycoprotein VI (GPVI);
• b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and
• c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet.

This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl). More particularly, this invention provides an agonist antibody to a human thrombopoietin receptor, wherein the agonist antibody comprises: antibody constant regions comprising (1) amino acid sequences in a heavy chain constant region and a light chain constant region of a human antibody, (2) an amino acid sequence of a heavy chain constant region with a domain substituted between human antibody subclasses, and an amino acid sequence of a light chain constant region of a human antibody, or (3) amino acid sequences comprising a deletion(s), substitution(s), addition(s), or insertion(s) of one or several amino acid residues in the amino acid sequences of (1) or (2) above; and antibody variable regions capable of binding to and activating a human thrombopoietin receptor; and wherein the agonist antibody has the properties: (a) that the antibody induces colony formation at a concentration of 10,000 ng/ml or lower as determined by the CFU-MK colony formation assay using human umbilical-cord-blood-derived CD34+ cells; and (b) that the antibody has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less in the cell proliferation assay using UT7/TPO cell. Also provided is a pharmaceutical composition for treating thrombocytopenia comprising said antibody.

The present invention provides a human antibody or an active-fragment thereof that specifically binds to human platelet membrane glycoprotein VI and does not induce a human platelet aggregation independently; a cell that produces the antibody or its active-fragment; a pharmaceutical composition that comprises the antibody or its active-fragment as an active ingredient, and so on. The above-mentioned cell can be obtained for example, as follows: a peripheral-blood-lymphocyte of the human that produces an autologous antibody to GPVI is activated by in vitro immunization under specific conditions; a hybridoma with mouse myeloma cell is prepared; and then the hybridoma that produces a monoclonal antibody, which has a binding capacity to GPVI and has an activity that suppresses collagen-mediated agglutinability of the human platelet is selected.

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

A process for generating megacaryocyte by in vitro induction to umbilical blood cell CD34+ includes in vitro amplifying the CD34+ in the culture medium containing fetal calf serum, human SCF, human TPO and/or ligand flt-3 and inducing the generation of megacaryocytes in the non-serum culture medium containing human TPO, human interleukin 3(IL-3) and/or human GM-CSF. Its advantage is high inducing efficiency.

Methods for inducing calcium mobilization in cells through the application of nanosecond pulsed electric fields (“nsPEFs”) are provided. The invention also provides a method of increasing intracellular calcium in cells through the application of nsPEFs. In one embodiment of the invention, the cells are human platelets, whereby activation and aggregation of the platelets is induced. Methods for treating an injury, trauma, or loss of blood in a subject, through the application of nsPEFs are also provided.

The invention provides a method belonging to the field of cytometric bead array with high sensitivity for testing platelet specific antibody based on platelet basic experimental study. Platelet lysate is used to incubate the microsphere which is coated with platelet membrane glycoprotein monoclonal antibody, then goat-anti-human IgG polyclonal antibody labeled with phycoerythrin is added, which is analyzed in cytometric bead array. If autoantibodies exist on the surface of platelet, 'microsphere-platelet membrane glycoprotein monoclonal antibody-platelet membrane glycoprotein autoantibodies-goat-anti-human IgG polyclonal antibody labeled with phycoerythrin' complex structure is formed, the fluorescence intensity of the test microsphere is enhanced. The invention is easy to operate, and has mature technology, high sensitivity for testing platelet autoantibodies, which is good for basic experimental study of platelet antibody.

The invention belongs to the technical field of genetic engineering and transgenic engineering and in particular relates to a method for building mammary gland specific expression vectors of human thrombopoietin gene and goat beta-casein gene promoter. The vectors which are built are transferred to COS-7 and HC-11 cells and expressed on eukaryotic cell level verification hTPO. The built mammary gland specific expression vectors of the human thrombopoietin gene and the goat beta-casein gene promoter are applied to prepare a mammary gland bioreactor of transgenic animals and are expressed with high level in the milk of transgenic mammalian, and the vectors provide useful drug protein-hTPO for clinic. The mammary gland specific expression vectors of human thrombopoietin gene and goat beta-casein gene promoter which are provided by the invention provide a foundation for further research and development.

Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against α_IIbβ₃ integrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library screening strategy was used to isolate variants of peptides that selectively bound to α_IIbβ₃ integrin or to both α_IIbβ₃ and α_Vβ₃ integrins. Unique consensus sequences were identified within the identified peptides suggesting alternative molecular recognition events that dictate different integrin binding specificities. In addition, the engineered peptides prevented human platelet aggregation in a plasma-based assay and showed high binding affinity for α_IIbβ₃ integrin.

The invention discloses a primer group and a kit for detecting a human platelet alloantigen (HPA) gene. The primer group for detecting the human platelet alloantigen (HPA) gene comprises an HPA-6a primer pair, an HPA-6b primer pair, an HPA-15Gova primer pair, an HPA-15Govb primer pair and an internal reference primer pair. The kit of the invention realizes platelet genotyping and has great significance for effectively avoiding platelet specific immunity and selecting to transfuse blood products matched with HPA genotypes in clinical and blood transfusion.

Erythrocytes from a vertebrate animal other than a human that have been size reduced and treated with a fixing agent by conventional methods to resemble human platelets are further treated to achieve a size distribution that is detected in a consistent manner by different methodologies of blood cell counting. The further treatment includes heating to a denaturing temperature followed by a second treatment with a fixing agent. The resulting cells are useful as controls for calibrating and checking the accuracy of automated blood cell counting equipment.

The invention relates to a method of preparing an intra-dermally, intra-articularly, sub-dermally or topically administrable growth factor concentrate derived from human platelets. The method comprises the steps of suspending human platelets in multiple electrolyte isotonic solution; snap-freezing the suspension; thawing the frozen suspension; and sterile-filtering the suspension. In particular, in this method, a fixed number of platelets is suspended in a fixed volume of multiple electrolyte isotonic solution to obtain the required concentration of growth factors in the growth factor concentrate, snap-freezing of the suspension is carried out at a temperature of −120° C. to −200° C., thawing of the frozen suspension is carried out at 25° C. to 37° C., and cellular debris are separated from the thawed suspension and the resultant suspension of growth factors is diluted with an isotonic medium before sterile-filtering.

The invention relates to a non-serum animal cell culture used fetus cattle serum displace agent, which is formed by recombination human insulin growth factor-1:0.1g-0.5g/l, recombination human platelet sourced growth factor-B:0.1g-0.6g/l, recombination human alkali desmocyte growth factor: 0.05-0.4g/l, cattle transferring: 1g-5g/l, cattle serum protein (V component): 2g-15g/l, and mercaptoethanol 0.3-0.5mol/l.

The present invention discloses a serum-free and heterologous component-free mesenchymal stem cell culture medium and an application thereof, and firstly discloses the mesenchymal stem cell culture medium. The mesenchymal stem cell culture medium comprises a basal culture medium and a supplement, the basal culture medium is a DMEM/F12 culture medium, and the supplement is a human platelet lysate and/or human lipocalin 2. The present invention further discloses the application of the mesenchymal stem cell culture medium in culturing mesenchymal stem cells. The provided mesenchymal stem cell culture medium is free of serum and heterologous components, ensures safety of clinical application, is simple in components, good in batch-to-batch stability and strong in cell expansion ability in vitro, meets industrial transformation requirements, can well maintain immune regulation ability and multi-directional differentiation ability of the mesenchymal stem cells, and ensures effective functions in clinical treatment.

The invention relates to the technical field of biology, in particular to a mesenchymal stem cell culture solution. The mesenchymal stem cell culture solution is prepared from the following components: human platelet lysate, mycillin (Pen Strep), long-acting glutamine, a chemotactic factor XCL1, a chemotactic factor CCL3, a heat shock protein (HSP70), a telomerase inhibitor IFN-alpha 2b and a basal culture medium DMEM. The components of the stem cell culture solution are wide in source, cultured mesenchymal stem cells are high in purity, quick in proliferation and good in dryness, and the mesenchymal stem cell culture solution is suitable for extracorporeal large-scale culture to conduct preclinical study and related clinical study.

The invention relates to a polypeptide used for prevention and treatment of acute coronary syndrome and anticoagulation antithrombotic therapy and application thereof. A sequence of the polypeptide disclosed by the invention is P1 Pro-Ser-Hyp-Gly-Asp-TrpP2 Pro-Ser-Hyp-Gly-Asp-Trp-ArgP3 Pro-Ser-Lys-Gly-Asp-TrpP4 Pro-Ser-Val-Gly-Asp-TrpP5 Pro-Ser-Nva-Gly-Asp-Trp-ArgP6 Pro-Ser-Pro-Gly-Asp-TrpP7 Pro-Ser-Thz-Gly-Asp-Trp, the polypeptide is independently used or combined with aspirin, clopidogrel or heparin, is used for inhibiting platelet aggregation and thrombosis and is taken as an effective ingredient for preparing a medicine used for prevention and treatment of acute coronary syndrome, unstable angina and acute myocardial infarction and intervention therapy of anticoagulation antithrombotic therapy. The polypeptide provided by the invention can be combined with a human blood platelet GPIIb-IIIa receptor, and has the capabilities of blocking blood platelet aggregation induced by adenosine diphosphate, arachidonic acid and thrombin and effectively inhibiting coronary thrombosis and femoral thrombosis.